- Home
- AGEN vs BEDU Comparison
AGEN vs BEDU Comparison
Compare AGEN & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- BEDU
- Stock Information
- Founded
- AGEN 1994
- BEDU 1994
- Country
- AGEN United States
- BEDU United Kingdom
- Employees
- AGEN N/A
- BEDU N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BEDU Other Consumer Services
- Sector
- AGEN Health Care
- BEDU Real Estate
- Exchange
- AGEN Nasdaq
- BEDU Nasdaq
- Market Cap
- AGEN 38.1M
- BEDU 44.9M
- IPO Year
- AGEN 2000
- BEDU 2017
- Fundamental
- Price
- AGEN $2.96
- BEDU N/A
- Analyst Decision
- AGEN Buy
- BEDU
- Analyst Count
- AGEN 4
- BEDU 0
- Target Price
- AGEN $8.00
- BEDU N/A
- AVG Volume (30 Days)
- AGEN 655.0K
- BEDU 19.7K
- Earning Date
- AGEN 05-06-2025
- BEDU 04-29-2025
- Dividend Yield
- AGEN N/A
- BEDU N/A
- EPS Growth
- AGEN N/A
- BEDU N/A
- EPS
- AGEN N/A
- BEDU N/A
- Revenue
- AGEN $103,463,000.00
- BEDU $231,461,038.00
- Revenue This Year
- AGEN $4.03
- BEDU N/A
- Revenue Next Year
- AGEN $5.57
- BEDU N/A
- P/E Ratio
- AGEN N/A
- BEDU N/A
- Revenue Growth
- AGEN N/A
- BEDU N/A
- 52 Week Low
- AGEN $1.38
- BEDU $1.35
- 52 Week High
- AGEN $19.69
- BEDU $2.42
- Technical
- Relative Strength Index (RSI)
- AGEN 78.44
- BEDU 45.13
- Support Level
- AGEN $1.60
- BEDU $1.47
- Resistance Level
- AGEN $1.83
- BEDU $1.78
- Average True Range (ATR)
- AGEN 0.31
- BEDU 0.19
- MACD
- AGEN 0.21
- BEDU -0.02
- Stochastic Oscillator
- AGEN 97.52
- BEDU 14.29
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.